Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

We're back in San Francisco, this time with Exelixis hosting our community mixer at their office.

This come-and-go networking event is open to all biopharma communicators in the T2B community. Complimentary snacks and drinks will be provided.

How Exelixis Grew Employee Volunteering 41% and Made the Business Case for Giving

Employee giving and volunteering can support several priorities at once: employee engagement, internal communications, social storytelling, and a company’s relationship and reputation with its local community and beyond. At Exelixis, these priorities come together in a Public Affairs-led program that grew employee volunteering 41% from 2024 to 2025.

In this case study, Kathleen Brennan and Lindsay Treadway will share how Exelixis creates a steady pipeline of engagement opportunities, uses a strategic year-round communications plan and channels to sustain participation, and partners across many internal departments to drive engagement among the Company’s employees. They will also discuss how external organizations and technology help a lean team expand its capacity, manage giving and volunteer activities, and capture meaningful data.

Attendees will gain a practical look at the operating model, communications approach, and measures of success that have helped Exelixis grow participation while strengthening employee sentiment, corporate storytelling, and its presence in the local community.

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit 

Q3 T2Bmeet @ SF 2026